Membranous nephropathy: The start of a paradigm shift

Current Opinion in Nephrology and Hypertension

Volumn 21, Issue 2, 2012, Pages 203-210

  Herrmann, Sandra M S ^a   Sethi, Sanjeev ^b   Fervenza, Fernando C ^a  

^a Mayo Clinic   (United States)

^b MAYO CLINIC   (United States)

Author keywords

ACTH; cationic bovine serum albumin; membranous nephropathy; PLA 2R antibodies; rituximab

Indexed keywords

ALBUMIN; ALDEHYDE REDUCTASE; ALPHA ENOLASE; ALPHA INTERMEDIN; BOVINE SERUM ALBUMIN; CORTICOSTEROID; CORTICOTROPIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; EPITOPE; FOOD ANTIGEN; GLYCEROPHOSPHOLIPID; HEPARAN SULFATE; HLA DQA1 ANTIGEN; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G1 ANTIBODY; IMMUNOGLOBULIN G4; MANGANESE SUPEROXIDE DISMUTASE; MANNOSE RECEPTOR; MEMBRANE METALLOENDOPEPTIDASE; PHOSPHOLIPASE A2; PHOSPHOLIPASE A2 RECEPTOR; PROOPIOMELANOCORTIN; PROTEOGLYCAN; RITUXIMAB;

ALBUMIN BLOOD LEVEL; ANCA ASSOCIATED VASCULITIS; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; B LYMPHOCYTE; DISEASE ACTIVITY; ENDOCYTOSIS; ENTERITIS; FOLLOW UP; GASTROENTERITIS; GENE FREQUENCY; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GLOMERULITIS; GLOMERULUS FILTRATION RATE; GLYCOCALYX; HEYMANN NEPHRITIS; HORMONAL THERAPY; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; KIDNEY BIOPSY; KIDNEY TRANSPLANTATION; MEMBRANOUS GLOMERULONEPHRITIS; MILK; NEPHROTIC SYNDROME; PH; PODOCYTE; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; T LYMPHOCYTE; TH2 CELL;

ADRENOCORTICOTROPIC HORMONE; ANTIBODIES; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; GENETIC PREDISPOSITION TO DISEASE; GLOMERULONEPHRITIS, MEMBRANOUS; HUMANS; IMMUNOLOGIC FACTORS; NEPRILYSIN; RECEPTORS, PHOSPHOLIPASE A2; SERUM ALBUMIN, BOVINE;

EID: 84857052152     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32835026ed     Document Type: Review

References (51)

1. Medawar W, Green A, Campbell E, et al. Clinical and histopathologic findings in adults with the nephrotic syndrome. Irish J Med Sci 1990; 159:137-140. (Pubitemid 20246827)
2. Kerjaschki D, Farquhar MG. The pathogenic antigen of Heymann nephritis is a membrane glycoprotein of the renal proximal tubule brush border. Proc Natl Acad Sci U S A 1982; 79:5557-5561. (Pubitemid 13197683)
3. Kerjaschki D, FarquharMG. Immunocytochemical localization of the Heymann nephritis antigen (GP330) in glomerular epithelial cells of normal Lewis rats. J Exp Med 1983; 157:667-686. (Pubitemid 13145068)
4. Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic membranous nephropathy: A one-year prospective study. J Am Soc Nephrol 2003; 14:1851-1857. (Pubitemid 36750480)
5. Maisonneuve P, Agodoa L, Gellert R, et al. Distribution of primary renal diseases leading to end-stage renal failure in the United States, Europe, and Australia/New Zealand: Results from an international comparative study. Am J Kidney Dis 2000; 35:157-165. (Pubitemid 30027256)
6. Fervenza FC, Sethi S, Specks U. Idiopathic membranous nephropathy: Diagnosis and treatment. Clin J Am Soc Nephrol 2008; 3:905-919.
7. Debiec H, Guigonis V, Mougenot B, et al. Antenatal membranous glomerulonephritis due to antineutral endopeptidase antibodies. N Engl J Med 2002; 346:2053-2060. (Pubitemid 34680597)
8. Debiec H, Nauta J, Coulet F, et al. Role of truncating mutations in MME gene in fetomaternal alloimmunisation and antenatal glomerulopathies. Lancet 2004; 364:1252-1259. (Pubitemid 39311346)
9. Ronco P, Debiec H. Antigen identification in membranous nephropathy moves toward targeted monitoring and new therapy. J Am Soc Nephrol 2010; 21:564-569.
10. Beck LH Jr., Bonegio RG, Lambeau G, et al. M-type phospholipase A2 receptor as target antigen in idiopathic membranous nephropathy. N Engl J Med 2009; 361:11-21.
11. Llorca O. Extended and bent conformations of the mannose receptor family. Cell Mol Life Sci 2008; 65:1302-1310.
12. Hoxha E, Harendza S, Zahner G, et al. An immunofluorescence test for phospholipase-A2-receptor antibodies and its clinical usefulness in patients with membranous glomerulonephritis. Nephrol Dial Transplant 2011; 26: 2526-2532.
13. Beck LH Jr., Fervenza FC, Beck DM, et al. Rituximab-induced depletion of anti-PLA2R autoantibodies predicts response in membranous nephropathy. J Am Soc Nephrol 2011; 22:1543-1550. Largest study to date to evaluate levels of anti-PLA2R antibodies and response to therapy. It also introduces the concept that proteinuria may persist despite disapearance of the antibody due to irreversible glomerular damage.
14. Hofstra JM, Beck LH Jr., Beck DM, et al. Antiphospholipase A receptor antibodies correlate with clinical status in idiopathic membranous nephropathy. Clin J Am Soc Nephrol 2011; 6:1286-1291. The study shows a correlation between presence of anti-PLA2R antibodies and disease activity.
15. Debiec H, Ronco P. PLA2R autoantibodies and PLA2R glomerular deposits in membranous nephropathy. N Engl J Med 2011; 364:689-690.
16. Debiec H, Martin L, Jouanneau C, et al. Autoantibodies specific for the phospholipase A(2) receptor in recurrent and de novo membranous nephropathy. Am J Transplant 2011; 11:2144-2152. Study reports that positive anti-PLA2R antibodies prior to kidney transplantation do not necessarely correlate with disease recurrence.
17. Prunotto M, Carnevali ML, Candiano G, et al. Autoimmunity in membranous nephropathy targets aldose reductase and SOD2. J Am Soc Nephrol 2010; 21:507-519. This study reports on a number of newly discovered antibodies in patients with membranous nephropathy.
18. Murtas C, Ravani P, Ghiggeri GM. New insights into membranous glomerulonephritis: From bench to bedside. Nephrol Dial Transplant 2011; 26:2428-2430.
19. Bruschi M, Carnevali ML, Murtas C, et al. Direct characterization of target podocyte antigens and auto-Antibodies in human membranous glomerulonephritis: Alfa-enolase and borderline antigens. J Proteomics 2011; 74:2008-2017.
20. Wakui H, Imai H, Komatsuda A, Miura AB. Circulating antibodies against alpha-enolase in patients with primary membranous nephropathy (MN). Clin Experiment Immunol 1999; 118:445-450.
21. Pratesi F, Moscato S, Sabbatini A, et al. Autoantibodies specific for alpha-enolase in systemic autoimmune disorders. J Rheumatol 2000; 27:109-115. (Pubitemid 30058637)
22. Hill GS. Tubulointerstitial nephritis and vasculitis. Curr Opin Nephrol Hypertens 1994; 3:356-363.
23. Moodie FD, Leaker B, Cambridge G, et al. Alpha-enolase: A novel cytosolic autoantigen in ANCA positive vasculitis. Kidney Int 1993; 43: 675-681. (Pubitemid 23071952)
24. Roozendaal C, de Jong MA, van den Berg AP, et al. Clinical significance of antineutrophil cytoplasmic antibodies (ANCA) in autoimmune liver diseases. J Hepatol 2000; 32:734-741. (Pubitemid 30262732)
25. Vermeulen N, Vermeire S, Arijs I, et al. Seroreactivity against glycolytic enzymes in inflammatory bowel disease. Inflamm Bowel Dis 2011; 17: 557-564.
26. Debiec H, Lefeu F, Kemper MJ, et al. Early-childhood membranous nephropathy due to cationic bovine serum albumin. N Engl J Med 2011; 364:2101-2110. The study demonstrates that modified bovine serum albumin is implicated in the pathogenesis of children with membranous nephropathy; it has clinical implications in the evaluation and treatment of children with this disease as well as raising the possibility that other dietary proteins could play a role in auto-immunity.
27. Mogues T, Li J, Coburn J, Kuter DJ. IgG antibodies against bovine serum albumin in humans: Their prevalence and response to exposure to bovine serum albumin. J Immunol Methods 2005; 300:1-11. (Pubitemid 40805583)
28. Border WA, Ward HJ, Kamil ES, Cohen AH. Induction of membranous nephropathy in rabbits by administration of an exogenous cationic antigen. J Clin Invest 1982; 69:451-461.
29. Chen JS, Chen A, Chang LC, et al. Mouse model of membranous nephropathy induced by cationic bovine serum albumin: Antigen dose-response relations and strain differences. Nephrol Dial Transplant 2004; 19:2721-2728. (Pubitemid 39480964)
30. Adler SG, Wang H, Ward HJ, et al. Electrical charge. Its role in the pathogenesis and prevention of experimental membranous nephropathy in the rabbit. J Clin Invest 1983; 71:487-499. (Pubitemid 13160794)
31. Ronco P, Debiec H. Advances in membranous nephropathy: Success stories of a long journey. Clin Exp Pharmacol Physiol 2011; 38:410-416.
32. Perez-Maceda B, Lopez-Bote JP, Langa C, Bernabeu C. Antibodies to dietary antigens in rheumatoid arthritis: Possible molecular mimicry mechanism. Clin Chim Acta 1991; 203:153-165.
33. Winer S, Astsaturov I, Cheung RK, et al. T cells of multiple sclerosis patients target a common environmental peptide that causes encephalitis in mice. J Immunol 2001; 166:4751-4756. (Pubitemid 32233764)
34. Feehally J, Farrall M, Boland A, et al. HLA has strongest association with IgA nephropathy in genome-wide analysis. J Am Soc Nephrol 2010; 21:1791-1797.
35. Gharavi AG, Kiryluk K, Choi M, et al. Genome-wide association study identifies susceptibility loci for IgA nephropathy. Nat Genet 2011; 43: 321-327.
36. Kim S, Chin HJ, Na KY, et al. Single nucleotide polymorphisms in the phospholipase A2 receptor gene are associated with genetic susceptibility to idiopathic membranous nephropathy. Nephron Clin Pract 2011; 117:c253-c258.
37. Liu YH, Chen CH, Chen SY, et al. Association of phospholipase A2 receptor 1 polymorphisms with idiopathic membranous nephropathy in Chinese patients in Taiwan. J Biomed Sci 2010; 17:81.
38. Stanescu HC, Arcos-Burgos M, Medlar A, et al. Risk HLA-DQA1 and PLA(2)R1 alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364:616-626. Study on the significant association of variants in genes encoding M-type phospholipase A2 receptor 1 and HLA-DQ alpha chain 1 in European patients with membranous nephropathy.
39. Bockenhauer D, Debiec H, Sebire N, et al. Familial membranous nephropathy: An X-linked genetic susceptibility? Nephron Clin Pract 2008; 108:c10-c15. (Pubitemid 351253439)
40. Short CD, Feehally J, Gokal R, Mallick NP. Familial membranous nephropathy. Br Med J 1984; 289:1500. (Pubitemid 15219280)
41. Kiryluk K. Risk alleles in idiopathic membranous nephropathy. N Engl J Med 2011; 364:2072-2073; author reply 2073-2074.
42. Berg AL, Nilsson-Ehle P, Arnadottir M. Beneficial effects of ACTH on the serum lipoprotein profile and glomerular function in patients with membranous nephropathy. Kidney Int 1999; 56:1534-1543. (Pubitemid 29451260)
43. Rauen T, Michaelis A, Floege J, Mertens PR. Case series of idiopathic membranous nephropathy with long-term beneficial effects of ACTH peptide 1-24. Clin Nephrol 2009; 71:637-642.
44. Berg AL, Arnadottir M. ACTH-induced improvement in the nephrotic syndrome in patients with a variety of diagnoses. Nephrol Dial Transplant 2004; 19:1305-1307. (Pubitemid 38628157)
45. Ponticelli C, Passerini P, Salvadori M, et al. A randomized pilot trial comparing methylprednisolone plus a cytotoxic agent versus synthetic adrenocorticotropic hormone in idiopathic membranous nephropathy. Am J Kidney Dis 2006; 47:233-240. (Pubitemid 43121326)
46. Bomback AS, Tumlin JA, Baranski J, et al. Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Drug Des Devel Ther 2011; 5:147-153. Preliminary data on the antiproteinuric effect of natural ACTH on patients with treatment-resistant membranous nephropathy.
47. Cattran DC, Delmore T, Roscoe J, et al. A randomized controlled trial of prednisone in patients with idiopathic membranous nephropathy. N Engl J Med 1989; 320:210-215. (Pubitemid 19034146)
48. Lindskog A, Ebefors K, Johansson ME, et al. Melanocortin 1 receptor agonists reduce proteinuria. J Am Soc Nephrol 2010; 21:1290-1298.
49. Fervenza FC, Cosio FG, Erickson SB, et al. Rituximab treatment of idiopathic membranous nephropathy. Kidney Int 2008; 73:117-125. (Pubitemid 350273646)
50. Fervenza FC, Abraham RS, Erickson SB, et al. Rituximab therapy in idiopathic membranous nephropathy: A 2-year study. Clin J Am Soc Nephrol 2010; 5:2188-2198. Largest prospective study to date to evaluate the use of rituximab in the treatment of membranous nephropathy and with the longest follow-up; also provides the most detailed pharmacokinetic as well as immunological studies in B and T cell subpopulations in these patients.
51. Cravedi P, Sghirlanzoni MC, Marasa M, et al. Efficacy and safety of rituximab second-line therapy for membranous nephropathy: A prospective, matched-cohort study. Am J Nephrol 2011; 33:461-468.